

Please type a plus sign (+) in this box → [+]

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL

Address to:

Assistant Commissioner for Patents
Box RCE
Washington, D.C. 20231

Application Number

09/694,519

Filing Date

10/23/2000

First Named Inventor

Robert Joseph Isfort

Group Art Unit

1637

Examiner Name

Teresa E. Strzelecka

Attorney Docket Number

8311

Confirmation Number

9641

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application.

NOTE: Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application.

1. Submission required under 37 C.F.R. § 1.114a. ☐ Previously submitted

i. ☐ Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on _____
(Any unentered amendment(s) referred to above will be entered).

ii. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____

iii. ☐ Other _____

b. Enclosed

i. ☒ Amendment/Replyii. ☐ Affidavit(s)/Declaration(s)iii. ☐ Information Disclosure Statement (IDS)iv. ☐ Other _____2. Miscellaneous

a. ☐ Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103(c) for a period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17(l) required)

b. ☐ Other _____

3. Fees The RCE fee under 37 C.F.R. § 1.17(e) is required by 37 C.F.R. § 1.114 when the RCE is filed.

☒ The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 16-2480.

i. ☒ RCE fee required under 37 C.F.R. § 1.17(e)

ii. ☒ Extension of time fee (37 C.F.R. §§ 1.136 and 1.17)

iii. ☐ Suspension of action fee under 37 C.F.R. 1.17(l)

iv. ☐ Other _____

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

NAME (Print/Type)

Naishadh N. Desai

Reg. No. (Attorney/Agent) 50,650

SIGNATURE

DATE January 3, 2003

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Box RCE, Washington, DC 20231, or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below:

NAME (Print/Type)

Naishadh N. Desai

SIGNATURE

02 FC:1001

750.00 CH

DATE January 3, 2003

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send Fees and Completed forms to the following address: Assistant Commissioner for Patents, Box RCE, Washington, D.C. 20231.

(Revised for P&G use 4/22/02)

+

#15/158
1/7/03
P&G Case 8311

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of
Robert J. Isfort et al.

Serial No. 09/694,519

Customer No. 27752

Confirmation No. 9641

Attorney Docket No. 8311

Filed: 10/23/2000

Art Unit: 1637

Examiner Teresa E. Strzelecka

For: Methods for Identifying Compounds for Regulating Muscle Mass or
Function Using Vasoactive Intestinal Peptide Receptors

REQUEST FOR CONTINUED EXAMINATION

Box RCE
Assistant Commissioner for Patents
Washington, D.C. 20231

RESPONSE TO FINAL OFFICE ACTION

Dear Sir:

In response to the final Office Action dated August 13, 2002, which provides a shortened statutory period for reply of three months thereafter, said response being extended by two (2) months, please charge any necessary fees to Applicants' Deposit Account No. 16-2480, please consider the following remarks.

REMARKS

The present invention relates to the use of VPAC receptors to identify candidate compounds that are potentially useful in the treatment of skeletal muscle atrophy and/or useful to induce skeletal muscle hypertrophy.

Claims 15, 16, 17, and 27 are pending in the application and are rejected by the examiner in the Final Office Action dated August 13, 2002.